Table 10.
Frequency of oncogenic driver mutation in our study cohort
| Study population (n = 469) | Patients testeda | |
|---|---|---|
| EGFR | 90/469 (19.2) | 90/469 (19.2) |
| KRAS | 159/469 (33.9) | 159/443 (35.9) |
| ALK | 28/469 (6.0) | 28/376 (7.4) |
| BRAF | 12/469 (2.6) | 12/309 (3.9) |
| ERBB2 | 9/469 (1.9) | 9/286 (3.1) |
| MET | 9/469 (1.9) | 9/234 (3.8) |
| PIK3CA | 7/469 (1.5) | 7/163 (4.3) |
| RET | 4/469 (0.8) | 4/208 (1.9) |
| ROS1 | 8/469 (1.7) | 8/248 (3.2) |
Data are absolute number of patients with percentages in parentheses
aPercentages in parentheses refer to the number of tested patients